Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 19;14:1327947. doi: 10.3389/fimmu.2023.1327947

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Hegen, Berek, Cavalla, Christiansen, Emeršič, Di Filippo, Gaetani, Hassler, Leurs, Milosavljevic, van Pesch, Petersen, Presslauer, Rosenstein, Rot, Schnabl, Teunissen, Vecchio, Vercellino and Deisenhammer

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

κ-FLC index in patients with primary progressive MS. (A) Number of patients (and κ-FLC index cut-off points) provided per MS centre². (B) Distribution of κ-FLC index³. (C) Prevalence of positive/negative κ-FLC index (using a cut-off of 6.1). (D) Prevalence of positive/negative OCB. (E) Agreement between κ-FLC index (using a cut-off of 6.1) and OCB. (F) Agreement between κ-FLC index (using the centre-specific cut-offs) and OCB. (G) Agreement between κ-FLC index using a cut-off of 6.1 or centre-specific cut-offs. ¹ Concordance was calculated as the number of positives revealed by both methods and the number of negatives revealed by both methods, related to the total number of patients, and expressed as percentage. ² Patients’ data were drawn out of following publications and/or recruited through following MS centres: 1 Leurs et al. Mult Scler 2020;26(8):912-923. 2 Cavalla et al. J Neuroimmunol 2020;339:577122 (n=11) and unpublished data of patients from AOU Città della Salute e della Scienza di Torino, Torino, Italy (n=28). 3 Emersic et al. Clin Chim Acta 2019;489:109-116 (n=8) and unpublished data of patients from University Medical Centre Ljubljana, Ljubljana, Slovenia (n=18). 4 Rosenstein et al. J Neurochem 2021;159(3):618-628. 5 Unpublished data of patients from Medical University of Innsbruck, Innsbruck, Austria. 6 Christiansen et al. Clin Chem Lab Med 2018;57(2):210-220. 7 Bayart et al. Acta Neurol Scand 2018;138(4):352-358. 8 Presslauer et al. Mult Scler 2016;22(4):502-10. 9 Presslauer et al. J Neurol 2008;255(10):1508-14. 10 Gaetani et al. J Neuroimmunol 2020;339:577108. 11 Vecchio et al. Sci Rep 2020;10(1):20329. ³ The horizontal, green, dashed line indicates a κ-FLC index at 6.1. FLC, free light chain; OCB, oligoclonal bands.